Yang Shen, PhD

VP Bispecifics and Antibody Engineering at Regeneron

Speaker

Yang Shen joined Regeneron in 2018 and currently serves as Vice President, Bispecifics and Antibody Engineering. Yang founded Antibody Engineering Group and played instrumental role in establishing Regeneron’s multispecific Altibody platform. He also served as co-chair for Protein Therapy, Pipeline and Technology Section. Yang leads the effort developing next-gen bispecifics and alternative format platforms and therapies at Regeneron. He received his Bachelor Degree from Peking University, China and Ph.D. in Structural Biology from Columbia University. Prior to joining Regeneron, Yang held increasing roles at ImClone Systems and Eli Lilly between 2008 and 2018.